Health Care Supplies

UGHealthcare

UGHealthcare released FY2026 Q1 earnings on February 11, 2026 (SGT) with actual revenue of SGD 37.34 M and EPS of SGD -0.0009

UGHealthcare released FY2026 Semi-Annual earnings on February 11 After-Market (SGT), actual revenue SGD 74.68 M, actual EPS SGD -0.0018

UGHealthcare released FY2026 Q2 earnings on February 11 After-Market (SGT), actual revenue SGD 37.34 M, actual EPS SGD -0.0009

UGHealthcare FY2026 Semi-Annual Earning Release on February 11, 2026 (SGT)

UGHealthcare released FY2025 9 Months Earnings on August 28, Post-Market (SGT), with actual revenue of SGD 108.37 M and EPS of SGD -0.0038

UGHealthcare released FY2025 Q3 earnings on August 28, 2025 (SGT) with actual revenue of SGD 35.7M and EPS of SGD -0.0025

UGHealthcare released FY2025 Annual Earnings on August 28 After-Market (SGT), actual revenue SGD 144.07 M, actual EPS SGD -0.0065

UGHealthcare released FY2025 Q4 earnings on August 28 After-Market (SGT), actual revenue SGD 35.7 M, actual EPS SGD -0.0025

UGHealthcare FY2025 Annual Earnings Release on August 28, 2025 After-Market (SGT)

UGHealthcare released FY2025 Q1 earnings on February 14 (SGT), with actual revenue of 36.33 M SGD and EPS of -0.0007 SGD

UGHealthcare released FY2025 Q2 earnings on February 14 After-Market (SGT), actual revenue 36.33 M SGD, actual EPS -0.0007 SGD

UGHealthcare released FY2025 Semi-Annual Earnings on February 14 After-Market (SGT), with actual revenue of 72.67 M SGD and EPS of -0.0015 SGD

UGHealthcare to Release FY2025 Semi-Annual Earnings on February 14, 2025 (SGT)

UGHealthcare released FY2024 9 Months earnings on August 29 (SGT), actual revenue SGD 82.45 M, actual EPS SGD -0.0071

UGHealthcare released FY2024 Q3 earnings on August 29 (SGT), actual revenue SGD 32.75 M, actual EPS SGD 0.0008

UGHealthcare released FY2024 Q4 earnings on August 29 After-Market (SGT), actual revenue SGD 32.75 M, actual EPS SGD 0.0008

UGHealthcare released FY2024 Annual Earnings on August 29 After-Market (SGT), actual revenue SGD 115.21 M (forecast SGD 201.5 M), actual EPS SGD -0.0063 (forecast SGD 0.04)

SingtelMBeCW260730

Abundance

Geely MB ePW261005

Asiatic

HSI 28000MBePW260629

Alibaba MB eCW260703

Teho

P-Nova Short MSSG-1X USy

NKY 55000MBePW260911

NKY 52000MBePW260612

<p>The Global Luminex Multiplex Assays Market is projected to grow from USD 1.82 billion in 2025 to USD 3.89 billion by 2033, at a CAGR of 10.0%. This growth is driven by the rising demand for high-throughput biomarker profiling and standardized testing workflows. Key factors include the efficiency of multiplex systems, regulatory support for standardized panels, and the expansion of outsourced research models. However, challenges such as validation complexity and elevated costs may impact adoption rates.</p>

fidelity

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

<p>Chinese rehabilitation robot manufacturers are expanding into international markets, leveraging technological advancements despite facing regulatory challenges. Experts highlight the rapid development of robot technology and the importance of partnerships for market entry. The global rehabilitation equipment market is projected to grow significantly, driven by an aging population and increasing health issues. Companies are adapting their strategies to meet varying market receptiveness, particularly in Europe and the U.S.</p>

Yicai

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

UGHealthcare(8K7.SG)

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say